Read by QxMD icon Read

Drug Metabolism and Personalized Therapy

Lucinda Rawlings, Laura Turton, Stephen C Mitchell, Glyn B Steventon
Background The S-oxidation of S-carboxymethyl-L-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson's disease and amyotrophic lateral sclerosis. In the present investigation, the original observations have been extended and confirmed. Methods Meta-analysis of previously published investigations into the S-oxidation polymorphism together with new subject data was evaluated. Results The incidence of the poor metaboliser phenotype (no urinary recovery of S-oxide metabolites) was found to be 3%-7% within healthy and non-neurological disease populations, whereas 38% of the Parkinson's disease subjects and 39% of the amyotrophic lateral sclerosis group were phenotyped as poor metabolisers...
April 2, 2019: Drug Metabolism and Personalized Therapy
Efstathia Giannakopoulou, Fotios Konstantinou, Georgia Ragia, Zisis Gerontitis, Anna Tavridou, Andreas Papapetropoulos, Dimitrios Mikroulis, Vangelis G Manolopoulos
Background Cystathionine γ-lyase enzyme, which is encoded by the CTH gene, is responsible for hydrogen sulfide (H2S) production in the endothelium. The CTH 1364 G>T polymorphism may alter the CTH expression and H2S bioavailability, thus leading to atherosclerosis and coronary artery disease (CAD). We examined the potential association of the CTH 1364 G>T polymorphism with CAD. Methods The CTH 1364 G>T polymorphism was determined in 178 coronary artery bypass grafting (CABG) patients and 156 non-atherosclerotic controls of Greek Caucasian origin using the PCR-RFLP method...
March 12, 2019: Drug Metabolism and Personalized Therapy
Francesco Rucci, Maria Sole Cigoli, Valeria Marini, Carmen Fucile, Francesca Mattioli, Luigi Robbiano, Ugo Cavallari, Francesco Scaglione, Carlo F Perno, Silvana Penco, Alessandro Marocchi
Background The thiopurine S-methyltransferase (TPMT)/azathioprine (AZA) gene-drug pair is one of the most well-known pharmacogenetic markers. Despite this, few studies investigated the implementation of TPMT testing and the combined evaluation of genotype and phenotype in multidisciplinary clinical settings where patients are undergoing chronic therapy with AZA. Methods A total of 356 AZA-treated patients for chronic autoimmune diseases were enrolled. DNA was isolated from whole blood and the samples were analyzed for the c...
March 6, 2019: Drug Metabolism and Personalized Therapy
Katsuhito Nagai, Shuhei Fukuno, Anna Omachi, Sachiko Omotani, Yasutoshi Hatsuda, Michiaki Myotoku, Hiroki Konishi
Background Menthol is widely used as a constituent of functional foods and chemical drugs. In the present study, we investigated changes in the expression of cytochrome P450 isoform CYP3A4mRNA after treating human hepatocellular carcinoma HepG2 cells with menthol. We also examined the effects of pretreatment with menthol on the cytotoxic activity of paclitaxel (PAC) and vincristine (VIN), which are substrates of CYP3A4, in the cells. Methods HepG2 cells were maintained in Dulbecco's Modified Eagle's Medium...
March 6, 2019: Drug Metabolism and Personalized Therapy
Dominique Vodovar, Bruno Mégarbane
No abstract text is available yet for this article.
February 28, 2019: Drug Metabolism and Personalized Therapy
Hossein Ali Mehralian, Jafar Moghaddasi, Hossein Rafiei
Background The present study was conducted with the aim of investigating the prevalence of potentially beneficial and harmful drug-drug interactions (DDIs) in intensive care units (ICUs). Methods The present cross-sectional prospective study was conducted in two ICUs in Shahr-e Kord city, Iran. The study sample was consisted of 300 patients. The Drug Interaction Facts reference text book [Tatro DS. Drug interaction facts. St Louis, MO: Walters Kluwer Health, 2010.] was used to determine the type and the frequency of the DDIs...
March 19, 2019: Drug Metabolism and Personalized Therapy
Lejla Mahmutovic, Tamer Bego, Maria Sterner, Gabriella Gremsperger, Emma Ahlqvist, Zelija Velija Asimi, Besim Prnjavorac, Nour Hamad, Adlija Causevic, Leif Groop, Sabina Semiz
Background Previous studies reported conflicting results regarding association of insulin receptor substrate 1 (IRS1) gene variation with type 2 diabetes (T2D) and insulin resistance (IR) in different ethnic groups. We examined the association of rs7578326, rs2943641, and rs4675095 in the IRS1 gene with T2D and related traits in a population from Bosnia and Herzegovina, which is one of the European countries with the highest T2D prevalence of 12.5%. Methods Our study included 390 T2D patients and 252 control subjects...
March 19, 2019: Drug Metabolism and Personalized Therapy
Mehran Alavi, Mehrdad Hamidi
Considerable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer...
February 1, 2019: Drug Metabolism and Personalized Therapy
Adrián LLerena, Heike Jahnke
No abstract text is available yet for this article.
December 19, 2018: Drug Metabolism and Personalized Therapy
Gerard Marshall Raj, Jayanthi Mathaiyan, Mukta Wyawahare, Rekha Priyadarshini
Background This work aimed to evaluate the influence of single nucleotide polymorphisms (SNPs) in the SLC47A1 (922-158G>A; rs2289669) and SLC47A2 (-130G>A; rs12943590) genes on the relative change in HbA1c in type 2 diabetes mellitus (T2DM) patients of South India who are taking metformin as monotherapy. It also aims to study the effects of these SNPs on the dose requirement of metformin for glycemic control and the adverse effects of metformin. Methods Diabetes patients on metformin monotherapy were recruited based on the eligibility criteria (n=105)...
December 19, 2018: Drug Metabolism and Personalized Therapy
Yuri Takahashi, Mio Sakuma, Hiroki Murayama, Takeshi Morimoto
Background The impact of renal and hepatic dysfunction on the morbidity and mortality of inpatients with adverse drug events (ADEs) is uncertain in daily clinical practice. The objective of this study was to investigate the effect of renal and hepatic function on ADEs and inpatients' morbidity and mortality. Methods The Japan Adverse Drug Events (JADE) study was a prospective cohort study carried out at three tertiary-care teaching hospitals in Japan. Participants were consecutive inpatients (n=3459) aged 15 years or older...
December 19, 2018: Drug Metabolism and Personalized Therapy
Ana E Rodríguez Vicente, Maria José Herrero Cervera, María Luisa Bernal, Luis Rojas, Ana M Peiró
Research and innovation in personalized medicine (PM) are extensive and expanding, with several pharmacogenetic/pharmacogenomic (PGx) testing options currently available for a wide range of health problems. However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by practitioner/patient: utilization and uptake by payers in real-world practice are being discussed, and the criteria to guide clinicians and policy makers in PGx test selection are not fully incorporated...
December 19, 2018: Drug Metabolism and Personalized Therapy
Michael S Zastrozhin, Anastasiya P Antonenko, Elena V Nesterenko, Leyla I Seyfullaeva, Violetta R Mustafina, Antonina P Esakova, Elena A Grishina, Alexandr S Sorokin, Valentin Yu Skryabin, Ludmila M Savchenko, Evgeny A Bryun, Dmitry A Sychev
Background Bromodihydrochlorophenylbenzodiazepine (Phenazepam®) is used in the therapy of anxiety disorders in patients with alcohol dependence. However, Phenazepam therapy often turns out to be ineffective, and some patients develop dose-related adverse drug reactions (ADR): severe sedation, dizziness, headache, dyspepsia, falling, etc. That ensures the effectiveness of this category of patients. Despite the popularity of Phenazepam® as an anxiolytic drug, there is currently no accurate data on its biotransformation, as well as the effect of polymorphism of a gene on the efficacy and safety of bromodihydrochlorophenylbenzodiazepine in patients...
December 19, 2018: Drug Metabolism and Personalized Therapy
Denis S Fedorinov, Karin B Mirzaev, Violetta R Mustafina, Dmitriy A Sychev, Nadezda R Maximova, Jana V Chertovskikh, Nyurguiana V Popova, Sardana M Tarabukina, Zoya A Rudykh
Background The aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied. Methods The study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12...
December 19, 2018: Drug Metabolism and Personalized Therapy
Mohammed Zawiah, Al-Motassem Yousef, Taha Kadi, Mohammed Yousef, Khalil Majdalawi, Shorouq Al-Yacoub, Rasha Al-Hiary, Dua'a Tantawi, Ramzi Mukred, Abdel Rahman Ajaj
Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy. Case presentation Interindividual variability in the efficacy of adjuvant chemotherapy between patients receiving the same treatment may be ascribed to the patients' genetic profile. In this report, we highlight a clinical case of a patient with stage II CRC who relapsed within a short period after starting adjuvant chemotherapy and was later found to have multiple genetic polymorphisms in the DPYD, TYMS, MTHFR, and DHFR genes...
December 19, 2018: Drug Metabolism and Personalized Therapy
Karin B Mirzaev, Eric Rytkin, Kristina A Ryzhikova, Elena A Grishina, Zhannet A Sozaeva, Denis S Fedorinov, Olga D Konova, Michael Iu Giliarov, Galina A Belyakova, Denis A Andreev, Dmitriy A Sychev
No abstract text is available yet for this article.
September 25, 2018: Drug Metabolism and Personalized Therapy
Natalia N Eremenko, Eugenia V Shikh, Svetlana Y Serebrova
No abstract text is available yet for this article.
September 25, 2018: Drug Metabolism and Personalized Therapy
Saul Flores-Unzueta, Martha Sosa-Macias, Laurence A Marchat, Ismael Lares-Assef, Omar Carrasco-Ortega, Miguel Correa-Ramirez, Fernando Guerrero-Romero, Carlos Galaviz-Hernandez
No abstract text is available yet for this article.
September 25, 2018: Drug Metabolism and Personalized Therapy
Minal U Paradkar, Swarup A V Shah, Alpa J Dherai, Dhanashri Shetty, Tester F Ashavaid
No abstract text is available yet for this article.
September 25, 2018: Drug Metabolism and Personalized Therapy
Shahin Nilchi, Davood Behdarvand, Hoda Lavasani, Mohammadreza Rouini, Yalda H Ardakani
No abstract text is available yet for this article.
September 25, 2018: Drug Metabolism and Personalized Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"